Pfizer India Shares rises 10% After a 85% Jump in Q4 Profit and ₹165 Dividend Announcement

Pfizer Ltd., the Indian arm of the global pharmaceutical giant, reported a strong financial performance for the fourth quarter of FY25, leading to a 10% surge in its share price.

Q4 FY25 Financial Highlights

In the quarter ending March 31, 2025, Pfizer India posted a net profit of ₹331 crore, marking an 85% increase compared to ₹179 crore in the same period last year. Revenue from operations rose by 8.3% year-on-year to ₹591.9 crore.

The company's earnings before interest, tax, depreciation, and amortisation (EBITDA) stood at ₹227.5 crore, up 20.1% from the previous year. The EBITDA margin improved to 38.4% from 34.7% in Q4 FY24.

Dividend Declaration

Pfizer India's Board of Directors recommended a total dividend of ₹165 per equity share for FY25. This includes a final dividend of ₹35 per share, a special dividend of ₹100 per share to commemorate the company's 75th year in India, and an additional ₹30 per share arising from gains on the transfer of leasehold land and building.The record date for determining shareholders' entitlement to the dividend is set for July 9, 2025.

Market Reaction

Following the announcement, Pfizer's stock experienced significant investor interest. The share price climbed up to 11.33%, reaching an intraday high of ₹4,970.40 on the Bombay Stock Exchange. The counter closed the day at ₹4,890/share with a significant rise of 9.44%.

Company Overview

Pfizer Ltd. is a leading pharmaceutical company in India, engaged in the discovery, development, and delivery of healthcare solutions. With a presence spanning over 170 years globally, Pfizer operates in more than 125 countries. In India, the company has a significant footprint, including a manufacturing facility in Goa that supports both domestic and international markets.

The company's portfolio encompasses key therapeutic areas such as vaccines, oncology, internal medicine, and rare diseases. Pfizer is known for its contributions to vaccine development, including the use of mRNA technology in its COVID-19 vaccine.

Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.

To read the RA disclaimer, please click here